Listen on the go
CORRECT!
Next question
touchOPHTHALMOLOGY touchOPHTHALMOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Ocular Immunology

    An Introduction to Uveitis and Ocular Immunology

    Uveitis is a leading cause of irreversible blindness in the developed world. First-line treatment involves corticosteroids followed by immunosuppressant therapy and an anti-tumour necrosis factor-alpha (TNF-α agent). Further investigation into new immunotherapies targeting different immune components is promising for the future.

    Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.

    Ocular Immunology Content

    Ocular Immunology
    Noninfectious Uveitis: A Review of Ophthalmic Management and Clinical Pearls
    Luke G Qin, Michael T Pierce, Rachel C Robbins

    touchREVIEWS in Ophthalmology. 2024;19(1):1–8:Online ahead of journal publication

    The uvea is a vascular stratum that includes the iris, ciliary body and choroid. Uveitis is defined as inflammation of a part of the uvea or its entirety, but it is also used to describe inflammatory processes of any part of the eye, such as the vitreous or peripheral retina. The clinical taxonomy of uveitis […]

    Ocular Immunology
    Watch Time: 37 mins
    touchPANEL DISCUSSION
    Thyroid eye disease: An evolving continuum of care
    CE/CME ACCREDITED Dr Andrea Kossler, Dr Edsel Ing, Dr Mario Salvi Translations available:

    Three experts discuss the underlying mechanisms of thyroid eye disease, risk factors, symptoms and diagnosis

    Learning objectives
    Learning Objectives
    • Understand the pathophysiology of TED and identify those who are most at risk for developing the disease
    • Recognize the signs and symptoms of TED and the burden of disease in affected patients
    • Describe the process for screening and diagnosing TED
    Ocular Immunology
    Study reveals elevated cataract risk in paediatric uveitis patients

    Findings from a recent cohort study published in JAMA Network Open suggest that paediatric patients with uveitis are at significant risk of cataract development.

    Ocular Immunology
    500x309-ophth8.png
    Advances in the Medical Treatment of Thyroid Eye Disease: Current and Emerging Therapies
    Clara Jiayun Men, Andrea Lora Kossler

    touchREVIEWS in Ophthalmology. 2024;18(1):33-40

    Thyroid eye disease (TED) is an autoimmune condition that can lead to significant visual impairment, facial disfigurement and decreased quality of life. It affects 16 out of every 100,000 females and 2.9 out of every 100,000 males. Risk factors for TED include age, female gender, smoking and radioactive iodine therapy.1 TED typically begins with a progressive […]

    Ocular Immunology
    Lisa Sarfaty: Help support Rare Disease Day

    Our society partner, NORD (The National Organization for Rare Disorder) has planned several initiatives to support this year’s Rare Disease Day on 28 February.  These activities are aimed at raising awareness about rare diseases and the challenges faced by people living with these conditions.  In this video, Lisa Sarfaty, NORD’s VP of Communication and Engagement, […]

    Ocular Immunology
    Lisa Sarfaty: Exploring and addressing inequities in rare diseases

    Rare diseases can present numerous challenges for those living with these conditions and the healthcare professionals caring for them. In this interview we discuss some of these with Lisa Sarfaty, VP of Communication and Engagement for NORD (The National Organization for Rare Disorders) and explore ways in which they could be tackled.  Questions Could you […]

    Ocular Immunology
    Immunosuppressive Therapy in Giant Cell Arteritis: Do Steroids Still Reign Supreme?
    Michael Y Zhao, Ujalashah Dhanani, Chaow Charoenkijkajorn

    touchREVIEWS in Ophthalmology. 2022;16(2):85–91 DOI: https://doi.org/10.17925/USOR.2022.16.2.85

    Giant cell arteritis (GCA) is a medium-to-large vessel vasculitis that affects branches of the thoracic aorta, including the carotid artery.1–4 The most feared ophthalmic complication is blindness (seen in up to ~25% of cases) due to arteritic ischaemic optic neuropathy involving ophthalmic artery circulation (e.g. retinal, choroidal or optic nerve). GCA may also lead to serious […]

    Ocular Immunology
    Carlos Pavesio, EURETINA 2021: Fluocinolone Acetonide Insert – A Study

    We were delighted to catch up with Carlos Pavesio (Moorfields Eye Hospital, London, UK), who shared details of his study to evaluate the safety and efficacy of the fluocinolone acetonide insert for the treatment of noninfectious uveitis. Questions: What were the aims and design of your recent study? (00:31) What were the efficacy and safety […]

    Ocular Immunology
    Carlos Pavesio, EURETINA 2021: Fluocinolone Acetonide Insert for Noninfectious Uveitis

    It was great to speak with Carlos Pavesio (Moorfields Eye Hospital, London, UK) about unmet needs in treatment of noninfectious uveitis, and the clinical evidence supporting the efficacy of the fluocinolone acetonide insert.   Questions: What are the unmet needs in the treatment of noninfectious uveitis? (00:33) Could you tell us a little about the […]

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2024 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchOPHTHALMOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup